DB18192InvestigationalCell transplant therapies
CLBS12 is a GCSF-mobilized autologous cell therapy derived from CD34+ cells being investigated for the treatment of Buerger’s disease.
- Code names
- CLBS-12
Resolves to
Compound
What you can answer from here — as of September 15, 2023
Which companies are running trials of CLBS12, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account